/ EN

04 | Multidisciplinary consultant


MingMed Biotechnology R&D team features world class scientists and global industry leaders. The management team is comprised of senior managers and serial entrepreneurs from pharmaceutical company, investment firm and commercial organization. The core team members have known each other for more than 20 years with long standing trust.

Xiaoyu Hu, Ph.D.

Scientific Advisor

***** Prof. Xiaoyu Hu received her Bachelor of Medicine degree from Peking University and obtained her Ph.D. degree in immunology from Cornell University. She held the position of tenure track Assistant Professor at Weill Cornell Medical College prior to joining Tsinghua University in 2014. Currently she is Professor at Institute for Immunology, Tsinghua University. Dr. Hu’s research aims to better understand molecular mechanisms governing functionality of two key cell types involved in host defense and inflammatory responses, macrophages and intestinal epithelial cells. Dr. Hu has authored over 50 publications including corresponding-author research articles in journals such as Immunity, Nature Immunology, Cell Host & Microbe, Journal of Experimental Medicine and Nature Communications (citations > 5,000; h-index = 29). She is the recipient of multiple awards including Christina Fleischmann Award to Young Women Investigators from International Cytokine & Interferon Society, NSFC Distinguished Young Investigator Award, U.K. Royal Society Newton Advanced Fellowship, and Young Scholar Award from Arthritis Foundation.

Junxia Min, M.D., Ph.D.

Scientific Advisor

***** Prof. Junxia Min currently serves as a professor at Institute of Translational Medicine & The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Prof. Min’s laboratory is mainly focused on 3 areas: 1. Development of Effective Novel Cancer Therapeutics, such as CAR-T; 2. Healthy Aging/ Longevity: to design effective interventions for improving health span for aging populations. Prof. Min earned her Ph.D. from University of Missouri-Columbia in the United States in 2006. From 2006-2010, Dr. Min had her postdoctoral training at the Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, where she identified the important novel epigenetic regulatory mechanisms in tumorigenesis. Since 2010, Dr. Min joined Novartis Department of Oncology as a group leader. Her group discovered and functionally validated several novel targets and optimized CAR-T for further clinical drug development.

Baopan Wan

Scientific Advisor

***** Dr. Baopan Wan currently is a Professor of the College of Veterinary Medicine at China Agricultural University, Executive Director of the China Veterinary Association, Chairman of Medical Committee at Chinese Horse Industry Association, the Training Textbook Editor of Beijing Small Animal Physician Association Qualification Appraisal and National Appraisal, External Expert of Beijing Zoo Veterinary Hospital, and the expert receiving State Council Special Allowance. With more than 60 years of experiences in clinical diagnosis and treatment of small animals, he has rich experience in orthopedics and ophthalmology. He is specialized in complex and difficult surgical operations and is a pioneer in animal surgery and small animal clinical practice in China. His superb inhalation anesthesia technique is known as the "pioneer" of veterinary anesthesia. He also won the Lifetime Achievement Award of Beijing Pet Diagnosis and Treatment Industry.

Gary Novack Ph.D.

Regulatory Affair

***** Dr Gary Novack is the President of PharmaLogic Development and a Professor of Pharmacology and Ophthalmology at the School of Medicine at University of California, Davis. He is a board-certified clinical pharmacologist and medical writer, with over 25 years of experience in pharmaceutical research and development. He consults for over 100 pharmaceutical and medical device firms, preparing drug development plans, clinical protocols and reports, manuscripts, as well as INDs, IDEs, NDAs, PMAs, and PLAs for worldwide submission. He authored over 290 publications and abstracts in clinical pharmacology, ophthalmology, dermatology and neurosciences. Dr Novack serves on several volunteer boards, including UC Regents, UC Santa Cruz Foundation (President), UC Santa Cruz Alumni Association (President), Foundation Fighting Blindness.

William J. Brock, Ph.D., DABT


***** Dr. Brock is the Principal of Brock Scientific Consulting, LLC, and serves as an adjunct associate professor of Eshelman School of Pharmacy at the University of North Carolina, Chapel Hill. Dr. Brock has more than 35 years of experience in toxicology and served as a toxicology manager and toxicology director at DuPont, Unilever, and Otsuka. As an experienced consultant, he has provided services to pharmaceutical, food, medical equipment, chemical industry, and consumer products companies, including designing nonclinical safety study, providing toxicological position papers, assessing product risk and safety, and communication to global regulatory agencies (FDA, EMA, BfRAM, MHRA, PMDA, etc.). Dr. Brock is a fellow of American Toxicology Society. He has published more than 50 papers and edited 9 books on toxicology and preclinical safety research. He also served as associate editor or reviewer for 3 toxicology journals. Dr. Brock has been invited to more than 40 seminars around the world. Dr. Brock holds positions in multiple organizations, such as President of the American Board of Toxicity, Chairman of the Hazardous Air Polluting Substances (HAPS) Toxicology Committee, Chairman of the ILSI/HESI Project, etc.. Dr. Brock is serving on multiple expert groups and committees, including the International Pharmaceutical Excipient Council (IPEC), American College of Toxicology, Endowment Fund

Previous page

Home   丨   About Us   丨   Product and Pipeline   丨   Our Team   丨   News   丨   Career   丨   Contact

Address: 106 Fengze East Road, Nansha District, Guangzhou 
Email: ming-med@ming-med.com

Copyright © 2020 ming-med.com  保留所有权利  粤ICP备20029450号-1